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Background: Staphylococcus aureus bacteremia (SAB) is the Staphylococcal infections in blood, one of the most common and fatal 
bacterial infectious diseases worldwide in adults as well as children or neonates. Recently, some studies have yielded inconsistent 
findings about the association between methicillin-resistance and mortality in patients with SAB. We performed a meta-analysis to 
assess the impact of methicillin-resistance on mortality in children or neonates with S. aureus bacteremia.
Materials and Methods: We searched using electronic databases such as Ovid-Medline, EMBASE-Medline, and Cochrane Library, as 
well as five local databases for published studies during the period of 1 January 2000 to 15 September 2011. Two reviewers indepen-
dently selected articles in accordance with predetermined criteria and extracted prespecified data based on standardized forms. All 
cohort studies, which compared in-hospital mortality or SAB-related mortality in children and neonates with methicillin-resistant S. 
aureus (MRSA) infection to those with methicillin-susceptible S. aureus (MSSA), were included. We conducted meta-analysis using 
the fixed-effect model to obtain pooled estimates of effect. 
Results: Of 2,841 screened studies, seven cohort studies were finally selected for analysis. In children or neonates, MRSA bacteremia 
was associated with a higher mortality compared with MSSA bacteremia (pooled odds ratio [OR] 2.33, P = 0.0008, 95% confidence 
interval [CI] 1.42 to 3.82, I2 = 0%). Four studies reported SAB-related mortality, the pooled OR of these studies was 2.03 ( P = 0.29, 
95% CI 0.55 to 7.53, I2 = 0%). A significant increase in mortality associated with methicillin resistance was found in the subgroup 
analyses of the studies with only neonates (OR: 2.66, 95% CI: 1.46 to 4.85, P = 0.001), prospectively design ones (OR: 3.20, 95% CI: 
1.66 to 6.15, P = 0.0005,), the larger studies (OR: 2.89, 95% CI: 1.62 to 5.16, P = 0.0003) and the higher quality studies (OR: 2.76, 
95% CI: 1.50 to 5.06, P = 0.001).
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Introduction
Staphylococcus aureus is one of the major causative organ-
isms for community- and hospital-acquired infections as 
causing invasive diseases, not only in adults but also in neo-
nates and children [1]. Methicillin-resistant S. aureus (MRSA) 
bacteremia is resistant to beta-lactam antibiotics, limiting the 
use of antibiotics for treatment, and it is known to cause fetal 
infections throughout the world. 
As well as multidrug-resistant enteric bacteria, MRSA is 
known to spread healthcare settings rapidly under the in ap-
propriate infection control and cause hospital-acquired infec-
tions [2]. Since the late 1990s, MRSA has been increasing in 
not only hospital-acquired S. aureus infections but also com-
munity-acquired infections [3]. For that reason, there has re-
cently been a high level of interest in the development of in-
fection control plans to address this threat.
Compared with methicillin-susceptible S. aureus (MSSA), 
MRSA is known to cause higher morbidity and mortality and 
longer hospital stays [4, 5]. These findings, however, were 
mostly investigated in studies with adult subjects; two meta-
analyses with adult subjects reported that MRSA bacteremia 
significantly increases mortality relative to MSSA bacteremia 
[6, 7]. Despite increase of bacteremia due to MRSA in neo-
nates and children [8-11], results in those were not consistent 
across studies [12-15]. In addition, advancements in the treat-
ment for S. aureus bacteremia (SAB) have been made over the 
past decade, including the development of effective antibiot-
ics and various changes in medical environments, such as the 
strengthening of hospital infection control systems. Therefore, 
to better reflect actual circumstances in the current medical 
environment, we performed a systematic review and meta-
analysis to assess the impact of methicillin-resistance on mor-
tality in children and neonates with SAB based on published 
studies since 2000 that report mortality rates associated with 
both MRSA and MSSA bacteremia.
Materials and Methods
1. Search strategy 
We searched for all studies comparing MSSA bacteremia 
and MRSA bacteremia in terms of their impact on mortality 
published between January 2000 and September 2011 
through Ovid-MEDLINE, EMBASE, and Cochrane library da-
tabases in addition to the following 5 local databases: Kore-
aMed, National Assembly Library (NANET), Korean Studies 
Information Service System (KISS), Korean Medical Database 
(KMBASE), and Korea Institute of Science and Technology In-
formation (KISTI) providing information on Korean medical 
published research. We used the search filter recommended 
by the Scottish Intercollegiate Guidelines Network (SIGN) to 
efficiently identify the cohort study design suited the objectives 
of this study. We applied no language restriction in electronic 
database search and limited to studies involving humans. We 
used the common keywords related to Staphylococcus aureus 
bacteremia and MRSA. The search terms were as follows: 
“Bacteremia” OR “sepsis” OR “Staphylococcus aureus infec-
tion” OR “endocarditis” AND “methicillin-resistant Staphylo-
coccus aureus” OR “MRSA”. We also reviewed the bibliogra-
phies of relevant articles to identify additional publications. 
The search terms “neonates” and “children” were not included 
in the search process. In the last step of the study selection, 
studies were identified and classified to estimate the number 
of studies with adult subjects and neonates or children rele-
vant to the aim of this study. 
2. Study selection
In the first stage of the study selection, irrelevant studies 
were excluded by reviewing titles and abstracts. The full-text 
articles were reviewed in the second and third stages of the 
study selection process. Two authors (DA Park and SM Lee) 
independently reviewed the articles for eligibility with pre-de-
termined selection criteria, and subsequently resolved any 
disagreements by discussion together with clinical expert 
consultation. 
The study inclusion criteria were as follows: (1) studies com-
paring patients with S. aureus bacteremia and S. aureus endo-
Conclusions: MRSA bacteremia is associated with increased mortality compared with MSSA bacteremia in children or neo-
nates. Due to limited studies for mortality in children or neonates with SAB, further research is needed to evaluate the impact of 
methicillin resistance on mortality in those populations.  
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carditis; (2) studies comparing patients with MRSA bactere-
mia and MSSA bacteremia; (3) studies comparing mortality 
rates (all-cause mortality; SAB-related mortality); and (4) 
studies investigating children (18 years or younger) and neo-
nates. The study exclusion criteria were as follows: (1) not 
original research; (2) animal studies or pre-clinical studies; (3) 
not cohort studies; (4) studies published with only an abstract; 
(5) studies not published in Korean or English; and (6) dupli-
cate reports.
3. Data extraction and quality assessment
Using a standardized data extraction form two independent 
reviewers authors (DA Park and SM Lee) extracted pre-speci-
fied data: first author, publication year, country, research de-
sign, study period, study setting, disease and number of study 
populations, age and sex of populations between MRSA/
MSSA groups, results of outcomes(in-hospital mortality, in-
fection-related mortality). Quality assessment of each includ-
ed studies was performed independently by two authors using 
the Newcastle-Ottawa Scale (NOS) [17]. This NOS scale for co-
hort studies uses a star rating system (range: 0-9 stars) scoring 
three aspects of the study: selection (0-4), comparability (0-2) 
and outcomes (0-3). During the data extraction and quality 
assessment, any disagreements were resolved by discussion.
4. Data synthesis and analysis
Meta-analyses were conducted using Review Manager, ver-
sion 5.0 (RevMan, The Cochrane Collaboration, Oxford, UK. 
For the dichotomous outcomes such as all-cause mortality, 
in-hospital mortality, infection-related mortality, we calculat-
ed the odds ratio (OR) and 95% confidence interval (CI) using 
the fixed-effect model. To test for heterogeneity, the forest plot 
was checked visually, and then statistical heterogeneity was 
assessed using a Q test (a P < 0.10 was considered significant) 
and the I2 statistic as a quantitative measure. Statistical het-
erogeneity was defined as an I2 statistic equal to or greater 
than 50% [18].
Factors that may have had an effect on outcomes were pre-
determined to investigate the cause of heterogeneity between 
studies, and sub-group analyses were conducted by type of 
study populations (neonates or children vs. neonates), study 
design (prospective cohort study vs. retrospective cohort 
study), the number of study subjects (60 people or fewer vs. 
above 60 people (as a rule of thumb)) [19], and the number of 
NOS stars (under 8 stars vs. more than 8 stars). 
Publication bias was visually assessed using a funnel plot by 
plotting the inverse of the standard error against the log odds 
ratio. To examine for publication bias, the Egger regression 
asymmetry test [20] and the Begg and Mazumdar adjusted 
rank correlation test [21] were also conducted using software 
Stata 10.0 (Stata Corp., College Station, TX, USA). 
A P value threshold for statistical significance was set at less 
than 0.05 for pooled effect estimates. 
Results
1. Study characteristics
A total of 2,841 studies were identified through the search 
strategy (Fig. 1). Duplicate studies from each database were 
eliminated, and then 1,824 studies deemed irrelevant to this 
study through a review of titles and/or abstracts were exclud-
ed. A total of 159 studies were found not to include a compari-
son of clinical outcomes for MRSA and MSSA in SAB and, 
therefore, were excluded in the second stage of the study se-
lection process. In the third stage, the authors reviewed the 
full-text of 92 studies with the inclusion and exclusion criteria. 
A total of 7 studies [12-15, 22-24] were finally selected after the 
exclusion of 85 studies for the following reasons: (1) not in-
cluding children or neonates; (2) unable to extract mortality 
data; (3) not cohort studies; and (4) duplicate studies.
A total of seven cohort studies that enrolled 667 patients 
(191 for MRSA, 476 for MSSA) were selected and included for 
the meta-analysis. The population size in each study ranged 
from 18 to 288. Most of the studies were published since 2005 
Articles identified from electronic 
database searches
- Ovid-Medline (n = 952)
- Ovid-EMBASE (n = 1,357)
- Cochrane library (n = 198)
- Local DB (KoreaMed et al) (n = 334)
n = 2,841
Articles screened
n = 2,075
Full-text articles assessed for eligibility
n = 251
Potentially appropriate articles to be 
included in this review
n = 92
Excluded (not relevant) 
(n = 159)
Excluded (duplicates)
(n = 766)
Excluded (n=85)
• No children or neonates (n = 62)
• No outcome data (n = 13)
• Not cohort studies (n = 9)
• Duplicates (n = 1)Articles included in meta-analysis
n = 7
Figure 1. Study flow diagram.
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[12, 13, 15, 22-24]. In terms of study design, there were 5 retro-
spective cohort studies [12, 13, 15, 22, 24] and 2 prospective 
cohort studies [14, 23].
Of the 7 studies, 3 had been conducted in the United States 
[12, 13, 22], 1 in Korea [24], 1 in Tanzania [23], 1 in Israel [15], 
and 1 in Australia [14]. Except one Korean study [24], the re-
maining studies were published in English [12-15, 22, 23]. 
Most of the studies reported in-hospital mortality as the over-
all mortality rate [12, 14, 15, 22-24]. Kuint et al. [15] reported 
both all-cause mortality and sepsis-related mortality, and 
Burke et al. [13] reported only infection-related mortality. The 
main characteristics of the studies included in this review and 
meta-analysis are summarized in Table 1. 
2. Results of quality assessment
Quality assessment of each study is reported in Table 1. 
Table 1. Selected seven studies analysed in this study
No Author Year Country
Study 
period
Study design
Popu-
lations
N
Age/
Gestational 
agea
Male 
(%)
MRSA 
(n)
MSSA 
(n)
Outcomes
NOS 
(stars)
1 Hultén [22] 2010 USA
2001.8-
2007.7
Retrospective SAB 100
1 week-16.7 
years
NS 29 71
Hospital 
mortality
7
2 Burke [13] 2009 USA
2001.7-
2006.6
Retrospective SAB 150
1 day-17 
years
52 29 121
Infection-
related 
mortality
7
3 Hakim [12] 2007 USA
2000.1-
2004.12
Retrospective SAB 36
0-14.9 
years
58.3 14 22
Hospital 
mortality
7
4
Kayange 
[23]a
2010 Tanzania
2009.3-
2009.11
Prospective SAB 32
28-41 
weeks
NS 9 23
Hospital 
mortality
9
5 Kang [24]a 2007 Korea
2001.2-
2007.5
Retrospective SAB 18
23-40 
weeks
NS 14 4
Hospital 
mortality
7
6 Kuint [15]a 2007 Israel
1993.1-
2003.12
Retrospective SAB 43
23-42 
weeks
60.5 31 12
Hospital 
mortality, 
Sepsis-related 
mortality
8
7 Isaacs [14]a 2004 Australia
1992.1-
1998.12
Prospective
SA-
sepsis
288 28.9 weeks NS 65 223
Hospital 
mortality
8
NS, not stated; SA, Staphylococcus aureus ; SAB, Staphylococcus aureus bacteremia; NOS, the Newcastle-Ottawa Scale.
aStudies with only neonates.
Figure 2. Mortality: MRSA bacteremia versus MSSA bacteremia.
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When the quality of the included studies was assessed, 1 study 
with 9 stars [19], 2 studies with 8 stars [14, 15] and 4 studies 
with 7 stars [12, 13, 18, 20], were found. 
3. Results of data analysis
A total of seven studies were combined in the all-cause mor-
tality analysis with six reporting in-hospital mortality out-
comes [12, 14, 15, 22-24] and one reporting infection-related 
mortality outcome [13]. In the pooled analysis with the fixed-
effect model for all-cause mortality, there was no evidence of 
heterogeneity between-studies (χ2 = 4.40, P = 0.62, I2 = 0%). The 
pooled OR for the effect of methicillin resistance on mortality 
was 2.33 (95% CI: 1.42 to 3.82, P = 0.0008), indicating a signifi-
cant increase for mortality in patients with MRSA bacteremia 
(Fig. 2).
Among four studies which have reported infection-related 
mortality [12, 13, 15, 24], except two [12, 24] not reporting 
SAB-related mortality, remaining two studies [13, 15] were 
combined in the pooled analysis and showed no heterogene-
ity between the studies (χ2 = 0.33, P = 0.56, I2 = 0%). The pooled 
OR for infection-related mortality in patients with MRSA was 
2.03 (95% CI: 0.55 to 7.53), indicating the increasing tendency 
of infection-related mortality for MRSA without a statistically 
significant difference (P = 0.29) (Fig. 3).
The results of methicillin resistance on mortality are sub-an-
alyzed according to study population, study design, and sam-
ple size and the results of quality assessment and presented in 
Table 2. The pooled OR from the 3 studies [12, 13, 22] that in-
volved both neonates and children was 1.73 (95% CI: 0.71 to 
4.22, P = 0.23). From four neonates studies [14, 15, 23, 24], the 
pooled OR was 2.66 (95% CI: 1.46 to 4.851, P = 0.001) (Fig. 4). 
In terms of study design, the pooled OR from the 2 prospec-
Table 2. Mortality of S. aureus bacteremia: Subgroup analysis according to study design and participants
Subgroup
No. 
of studies
No. 
of participants
M-H, fixed,  
OR [95% CI]
P-value of 
Q-test 
I2 statistics
Participants
      Children+Neonates 3 286 1.73 [0.71-4.22] 0.25 29%
       Neonates 4 381 2.66 [1.46-4.85] 0.69   0%
Study design
       Prospective 2 320 3.20 [1.66-6.15] 0.65   0%
       Retrospective 5 347 1.60 [0.75-3.40] 0.55   0%
No. of participants
       > 60 3 538 2.89 [1.62-5.16] 0.99   0%
       ≤ 60 4 129 1.46 [0.58-3.67] 0.31 16%
No. of NOS stars
       ≥ 8 stars 3 363 2.76 [1.50-5.06] 0.57 0%
      < 8 stars 4 304 1.66 [0.70-3.96] 0.40 0%
M-H, Mantel-Haenszel; OR, odds ratio; No., number; CI, confidence interval; NOS, the Newcastle-Ottawa Scale.
Figure 3. Infection-related mortality: MRSA bacteremia versus MSSA bacteremia.
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tive cohort studies [14, 23] was 3.20 (95% CI: 1.66 to 6.15, P = 
0.0005), whereas the pooled OR from the 5 retrospective ones 
[12, 13, 15, 22, 24] was 1.60 (95% CI: 0.75 to 3.40, P = 0.22). 
With regard to sample size, 3 studies [13, 14, 22] involved sam-
ple size > 60 people, and 4 studies [12, 15, 23, 24] involved ≤ 60 
people; the OR from studies with more than 60 people was 
2.89 (95% CI: 1.62 to 5.16, P = 0.0003), and the OR from studies 
60 people or fewer was 1.46 (95% CI: 0.58 to 3.67, P = 0.42). 
There were three studies with NOS of more than 8 stars which 
showed OR 2.76 (95% CI: 1.50 to 5.06, P = 0.001), whereas four 
studies with NOS of under 8 stars showed OR 1.66 (95% CI: 
0.70 to 3.96, P = 0.25). 
No evidence of potential publication bias was noted in the 
funnel plot, the regression asymmetry test (P = 0.119), or the 
adjusted rank correlation test (P = 0.23).  
Discussion
This study conducted a systematic review and meta-analysis 
of cohort studies published since 2000 to quantify the effect of 
methicillin-resistance on mortality in neonates or children 
with SAB. The mortality rate was found to be significantly 
higher in patients with MRSA bacteremia, compared to rate in 
those with MSSA. 
A total of 7 cohort studies were included in the final analysis. 
The results of the analysis showed a significantly higher mor-
tality risk (OR = 2.33) in neonates or children with MRSA bac-
teremia than in those with MSSA bacteremia. We considered 
the possibility that estimating the mean mortality rate of 9.0% 
(43/476) in the control group with MSSA bacteremia based on 
the pooled OR could result in an overestimation of the effect 
size. This difference of the pooled estimate might have been 
influenced by the result from Isaacs et al.’s study [14], which 
had the largest sample size among combined studies and of 
which subjects been enrolled in the 1990’s; in consideration of 
these factors, a sensitivity analysis, excluding the Isaacs et al.’s 
study, showed that methicillin resistance have not significant-
ly increased the mortality rate (OR: 1.91, 95% CI: 0.97 to 3.77, 
P = 0.06). Although this sensitivity analysis did not obtain a 
statistical significance, the direction of effect was consistent 
with the pooled result of the overall mortality. 
Figure 4. Mortality of S. aureus bacteremia analysed by study population.
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In comparison of mortality rate between MRSA bacteremia 
and MSSA bacteremia in neonates or children, methicillin-re-
sistance is considered to be associated with an increase in 
mortality risk. This study is the first meta-analysis to investi-
gate the effect of methicillin-resistance on mortality in neo-
nates and children with SAB. The result was comparable to the 
OR, 1.93 (95% CI: 1.54 to 2.42) in a meta-analysis [7] which 
have been investigated among adult subjects. Although the 
pooled analysis for infection-related mortality in four com-
bined studies did not provide a statistically significant result, 
the direction of effect was in accordance with the hypothesis 
that methicillin-resistance increases the overall mortality in 
study population.
The significant association between resistance and mortality 
risk was found in the subgroup analysis only for neonate sub-
jects, not for mixed population of children and neonates. It 
might be because the number of studies in mixed population 
of children and neonate are too small to show the significant 
result, compared to that in neonate studies. More published 
studies targeting children are required to show the significant 
association between methicillin-resistance and increase of 
mortality in SAB. In subgroups stratified according to study 
design and sample size, a significant risk of methicillin-resis-
tance for mortality was found in prospectively designed 
groups, large population groups above 60 and higher quality 
groups more than 8 stars of NOS. 
The lack of a significant difference in some subgroups is due 
to the small number of included studies, which have resulted 
in insufficient power to identify the association between 
methicillin-resistance and risk for mortality in children and 
neonates with SAB. Out of seven primary studies, only Isaacs 
et al. [14] demonstrated a significant difference of mortality 
rates between patients with MRSA and MSSA bacteremia. Re-
maining six [12, 13, 15, 22-24] did not show any significant dif-
ference of those. In a meta-analysis by Cosgrove et al. [7], 
which investigated adult subjects, although 77.4% of the 31 
cohort studies failed to identify the impact of methicillin-re-
sistance on mortality, but the integrated results showed a evi-
dent association between MRSA bacteremia and mortality 
(OR: 1.93, 95% CI: 1.54 to 2.42). Similar to the result of Cos-
grove’s study, an increase in mortality rate of methicillin resis-
tance was demonstrated in the integrated results of our meta-
analysis, even though 85.7% of studies did not demonstrate an 
increase of mortality. 
Although the studies included in this meta-analysis had dif-
ferent subject characteristics, such as neonates vs. children or 
neonates, no statistical heterogeneity was identified, and be-
tween-study statistical heterogeneity was not found in any of 
the all pooled analyses. (I2 statistic: 0% to 29%). In the meta-
analysis by Cosgrove et al. [7], heterogeneity among the stud-
ies was quite high (Q test : P = 0.03). In this study, however, the 
heterogeneity test results were considerably lower than those 
in the general meta-analysis by Cosgrove et al. This indicates 
that between-study heterogeneity did not have a major impact 
on the results. Therefore, a wide distribution of subject charac-
teristics between studies in this meta-analysis is not consid-
ered to have had a huge impact on the study results. 
Publication bias has been considered to be a particular 
threat to the validity of meta-analysis of observational studies 
[25]. However, there was no evidence of publication bias in 
the current study. According to the Cochrane handbook, tests 
for funnel plot asymmetry should be used only when there are 
at least 10 studies included in the meta-analysis, because 
when there are fewer studies the power of the tests such as the 
Egger test, and Begg and Mazumdar rank correlation test is 
too low to distinguish chance from real asymmetry [26]. 
Therefore, the results of publication bias in this study should 
be cautiously interpreted, further research is needed to assess 
evidence to investigate the publication bias clearly .
This study is clinically meaningful in that it was the first 
study to conduct integrated analysis regarding mortality out-
comes of resistance in neonates and children with SAB. Based 
on studies published since 2000, our meta-analysis results in-
dicated that mortality rate in MRSA group is still higher than 
that in MSSA group despite advances in medical technology 
and environmental system. Prior to the year 2000, glycopep-
tides were the primary treatment option for MRSA infection. 
Around 2000, however, the FDA approved quinupristin-dalfo-
pristin, linezolid, daptomycin, and tigecycline, broadening 
treatment choices for MRSA. Hence, MRSA treatment out-
comes were expected to improve. As existing studies on the 
impact of MRSA are based on data collected prior to 2000, this 
study focused on studies published since 2000 to reevaluate 
the impact of MRSA in light of the introduction of new antibi-
otics into clinical practice. However, one limitation of this 
analysis is that it does not fully reflect the current medical en-
vironment, given that some of the primary studies included in 
this analysis had study periods earlier than 2000. 
The more severe condition of MRSA bacteremia patients 
compared with MSSA bacteremia patients may have account-
ed for the higher mortality rate, but none of the 7 studies in 
this analysis conducted multivariable analysis to identify 
methicillin-resistance as an independent predictive factor for 
mortality. Hultén et al. [22], however, reported that hospital-
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acquired S. aureucs infections accounted for mortality in 23 
out of 242 patients (9.5%), and at the time of death, all of these 
subjects had either bacteremia or catheter-associated infec-
tion. Among them, 10 (43.5%) had SAB, 6 (26.1%) were pre-
mature infants, and 7 (30.4%) were male. Kayange et al. [23] 
reported that having a positive blood culture test and MRSA 
are significant related factors that increase mortality in neo-
nates with sepsis. In the study published in Korea, Kang et al. 
[24] reported that the absence of SAB-related mortality in pa-
tients in the neonatal intensive care unit (NICU) was due to 
empirical antibiotic administration and vancomycin adminis-
tration in the high-risk group (those with very low birth 
weight, ventilation therapy, retention of the central venous 
catheter, and high baseline levels of C-reactive protein).
In conclusion, a significant association was found between 
methicillin-resistance and higher mortality rate in neonates 
and children, compared to susceptible one. Based on the inte-
grated results in comparison of mortality rate, MRSA bactere-
mia is associated with higher mortality risk compared with 
MSSA bacteremia, and this was consistent in results of sub-
groups with neonate subjects, prospective cohort studies, 
studies with large sample sizes and the higher quality studies. 
Due to limited number of studies for mortality in children and 
neonates with SAB, it is insufficient to draw the conclusion 
about mortality risk of methicillin-resistance on outcomes in 
study population. Hence, further studies are warranted in 
these areas.
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